English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 19 August 2015, 07:35 HKT/SGT
Share:
    

Source: Omnicare
Omnicare Announces Conversion Rate Adjustments for Convertible Notes

Cincinnati, Aug 19, 2015 - (ACN Newswire) - Omnicare, Inc. (the "Company") announced today an adjustment to the conversion rate of its (i) 3.75% Convertible Senior Subordinated Notes due 2025 (the "2025 Notes"), (ii) 3.50% Convertible Senior Subordinated Notes due 2044 (the "2044 Notes"), (iii) 3.25% Convertible Senior Debentures due 2035 (the "Debentures") and (iv) 3.25% Convertible Senior Exchange Debentures due 2035 (the "Exchange Debentures" and, together with the Debentures, the "2035 Debentures"). Effective August 18, 2015, the adjusted conversion rate for (i) the 2025 Notes is 37.7191 shares of common stock per $1,000 principal amount, (ii) the 2044 Notes is 14.3863 shares of common stock per $1,000 principal amount, provided, that, the conversion rate with respect to any conversions "in connection with" the Non-Stock Change of Control, as defined in the applicable indenture, is 15.2307 and (iii) the 2035 Debentures is 13.0483 shares of common stock per $1,000 principal amount; provided, that, the conversion rate with respect to any conversions "in connection with" the Non-Stock Change of Control, as defined in the applicable indenture, is 13.1278.

The conversion rates were initially adjusted in connection with the Company's regular quarterly dividend payments. The further adjustments to the conversion rates "in connection with" the Non-Stock Change of Control, are in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 20, 2015, by and among the Company, CVS Pharmacy, Inc., a Rhode Island corporation ("CVS Pharmacy"), and Tree Merger Sub, Inc. ("Merger Sub"), a Delaware corporation and wholly owned subsidiary of CVS Pharmacy, pursuant to which Merger Sub merged with and into the Company, with the Company continuing as the surviving company and a wholly owned subsidiary of CVS Pharmacy.

About Omnicare

Omnicare, Inc., a wholly owned subsidiary of CVS Health Corporation, provides comprehensive pharmaceutical services to patients and providers across the United States. As the market-leader in professional pharmacy, related consulting and data management services for skilled nursing, assisted living and other chronic care institutions, Omnicare leverages its unparalleled clinical insight into the geriatric market along with some of the industry's most innovative technological capabilities to the benefit of its long-term care customers. Omnicare also provides specialty pharmacy and key commercialization services for the bio-pharmaceutical industry through its Specialty Care Group. For more information, visit www.omnicare.com.

Contact:
Patrick C. Lee
+1-513-719-1507
patrick.lee@omnicare.com

###

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Omnicare via Globenewswire

Topic: Press release summary
Source: Omnicare


https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Omnicare Related News
Sept 16, 2015 07:55 HKT/SGT
Omnicare Trust PIERS to Accrue Contingent Interest
July 24, 2015 20:40 HKT/SGT
Omnicare Reports Second-Quarter 2015 Financial Results
June 20, 2015 06:05 HKT/SGT
Omnicare's Series A and Series B Trust PIERS to Accrue Contingent Interest
May 22, 2015 06:30 HKT/SGT
Omnicare Declares Quarterly Cash Dividend
Apr 2, 2015 08:20 HKT/SGT
Omnicare to Report First-Quarter 2015 Financial Results and Hold Conference Call on Wednesday, April 29, 2015
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575